These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20028756)

  • 1. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
    Su Y; Amiri KI; Horton LW; Yu Y; Ayers GD; Koehler E; Kelley MC; Puzanov I; Richmond A; Sosman JA
    Clin Cancer Res; 2010 Jan; 16(1):348-57. PubMed ID: 20028756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
    Kubicek GJ; Werner-Wasik M; Machtay M; Mallon G; Myers T; Ramirez M; Andrews D; Curran WJ; Dicker AP
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):433-9. PubMed ID: 19084346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
    Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S; Sullivan DM
    Clin Cancer Res; 2011 Mar; 17(5):1140-6. PubMed ID: 21233404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
    Portnow J; Frankel P; Koehler S; Twardowski P; Shibata S; Martel C; Morgan R; Cristea M; Chow W; Lim D; Chung V; Reckamp K; Leong L; Synold TW
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):505-14. PubMed ID: 21850464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
    Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
    Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
    Amiri KI; Horton LW; LaFleur BJ; Sosman JA; Richmond A
    Cancer Res; 2004 Jul; 64(14):4912-8. PubMed ID: 15256463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
    Trinh XB; Sas L; Van Laere SJ; Prové A; Deleu I; Rasschaert M; Van de Velde H; Vinken P; Vermeulen PB; Van Dam PA; Wojtasik A; De Mesmaeker P; Tjalma WA; Dirix LY
    Oncol Rep; 2012 Mar; 27(3):657-63. PubMed ID: 22134540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
    Dy GK; Thomas JP; Wilding G; Bruzek L; Mandrekar S; Erlichman C; Alberti D; Binger K; Pitot HC; Alberts SR; Hanson LJ; Marnocha R; Tutsch K; Kaufmann SH; Adjei AA
    Clin Cancer Res; 2005 May; 11(9):3410-6. PubMed ID: 15867242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
    Poklepovic A; Youssefian LE; Winning M; Birdsell CA; Crosby NA; Ramakrishnan V; Ernstoff MS; Roberts JD
    Invest New Drugs; 2013 Aug; 31(4):937-42. PubMed ID: 23315028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
    Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
    Badros A; Burger AM; Philip S; Niesvizky R; Kolla SS; Goloubeva O; Harris C; Zwiebel J; Wright JJ; Espinoza-Delgado I; Baer MR; Holleran JL; Egorin MJ; Grant S
    Clin Cancer Res; 2009 Aug; 15(16):5250-7. PubMed ID: 19671864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.
    Markowitz J; Luedke EA; Grignol VP; Hade EM; Paul BK; Mundy-Bosse BL; Brooks TR; Dao TV; Kondalasula SV; Lesinski GB; Olencki T; Kendra KL; Carson WE
    J Immunother; 2014 Jan; 37(1):55-62. PubMed ID: 24316557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
    LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
    Ryan DP; O'Neil BH; Supko JG; Rocha Lima CM; Dees EC; Appleman LJ; Clark J; Fidias P; Orlowski RZ; Kashala O; Eder JP; Cusack JC
    Cancer; 2006 Dec; 107(11):2688-97. PubMed ID: 17075878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Dreicer R; Petrylak D; Agus D; Webb I; Roth B
    Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
    Hamilton AL; Eder JP; Pavlick AC; Clark JW; Liebes L; Garcia-Carbonero R; Chachoua A; Ryan DP; Soma V; Farrell K; Kinchla N; Boyden J; Yee H; Zeleniuch-Jacquotte A; Wright J; Elliott P; Adams J; Muggia FM
    J Clin Oncol; 2005 Sep; 23(25):6107-16. PubMed ID: 16135477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.